Company profile for Gallant Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Gallant Therapeutics is an innovative animal health biotechnology company operating in the clinical stage. It is redefining standards in animal health by utilizing stem cell therapy to address the root causes of diseases in dogs and cats. The company's pipeline focuses on off-the-shelf mesenchymal stem cell (MSC) therapies with the potential to treat a wide range of conditions, including osteoarthritis (OA) in both canines and...
Gallant Therapeutics is an innovative animal health biotechnology company operating in the clinical stage. It is redefining standards in animal health by utilizing stem cell therapy to address the root causes of diseases in dogs and cats. The company's pipeline focuses on off-the-shelf mesenchymal stem cell (MSC) therapies with the potential to treat a wide range of conditions, including osteoarthritis (OA) in both canines and felines, chronic kidney disease (CKD) in felines, and others.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
SAN DIEGO, CA 92121
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/gallant-announces-first-of-its-kind-partnership-with-mwi-animal-health-to-deliver-anticipated-fda-conditionally-approved-stem-cell-therapy-into-veterinary-clinics-302699723.html

PR NEWSWIRE
27 Feb 2026

https://www.prnewswire.com/news-releases/fda-completes-safety-for-gallants-first-ready-to-use-stem-cell-therapy-for-refractory-fcgs-302610213.html

PR NEWSWIRE BIO
10 Nov 2025

https://www.prnewswire.com/news-releases/gallant-achieves-fda-technical-section-complete-for-reasonable-expectation-of-effectiveness-advancing-first-ready-to-use-stem-cell-therapy-302563870.html

PR NEWSWIRE
23 Sep 2025

https://www.globenewswire.com//news-release/2024/02/06/2824305/0/en/Gallant-Therapeutics-Adds-Animal-Health-Executive-Aaron-Schacht-to-Board-of-Directors.html

GLOBENEWSWIRE
06 Feb 2024

https://www.globenewswire.com//news-release/2024/01/08/2805396/0/en/Gallant-Therapeutics-Raises-Over-15-Million-in-Series-A-Funding-to-Advance-Pipeline-of-Off-the-Shelf-Stem-Cell-Therapies-for-Pets.html

GLOBENEWSWIRE
08 Jan 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty